

G.P. KAPADIA & CO

Chartered Accountants

*Hamam House
Ambalal Doshi Marg,
Mumbai - 400 001*

Tel. : 2265 4239, 2265 4313
E-mail : gpkco@yahoo.com

Limited Review Report for the half year ended 30th September, 2025 on Unaudited Standalone Financial Results of Unihealth Hospitals Limited (Formerly Known as Unihealth Consultancy Limited) under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

**To,
Board of Directors,
Unihealth Hospitals Limited
(Formerly Known as Unihealth Consultancy Limited)**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Unihealth Hospitals Limited** (herein after referred as 'the Company') (Formerly Known as *Unihealth Consultancy Limited*) for the Half Year ended 30th September 2025 (the 'Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations')
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of The Companies Act 2013, as amended, read with relevant rules issued thereunder and accounting principles generally accepted in India and in compliance with Regulation 33 of Listing Regulations. The statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of The Companies Act 2013, read with relevant Rules issued thereunder and other recognized accounting practices and policies generally accepted

G.P. KAPADIA & CO

Chartered Accountants

*Hamam House
Ambalal Doshi Marg,
Mumbai - 400 001*

Tel. : 2265 4239, 2265 4313
E-mail : gpkco@yahoo.com

in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For G.P Kapadia & Co.
(Chartered Accountants)**

FRN No.: 104768W

Atul Digitally signed
by Atul
Babubhai Babubhai Desai
Desai Date: 2025.11.14
18:16:14 +05'30'

Atul Desai

(Partner)

Membership No. 030850

Place: Mumbai

Date: 14th November, 2025

UDIN: 25030850BMGYJH6675

UNIHEALTH HOSPITAL LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER

		(Rs. In lakhs)			
	PARTICULARS	HALF YEAR ENDED		YEAR ENDED	
		30.09.2025	31.03.2025	30.09.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited
I	Revenue from operations	286.90	200.22	155.88	356.10
II	Other income	265.95	180.43	150.53	330.96
III	Total revenue (I + II)	552.85	380.65	306.41	687.06
IV	Expenses				
-	Cost of materials consumed	-	-	-	-
-	Purchases of stock in trade	-	58.84	-	58.84
-	trade	-	-	-	-
-	Employee benefits expense	87.02	83.92	78.52	162.44
-	Finance costs	8.27	3.07	0.18	3.25
-	Depreciation and amortization expense	12.43	14.86	13.37	28.23
-	Other expenses	80.29	52.24	58.24	110.48
V	Total Expense (IV)	188.01	212.93	150.31	363.24
VI	Profit/(Loss) before exceptional and extra-ordinary items and Tax (III - V)	364.84	167.72	156.10	323.82
VII	Exceptional Items	-	-	-	-
VIII	Profit/(Loss) before extra-ordinary items and Tax	364.84	167.72	156.10	323.82
IX	Extra-Ordinary Items	-	-	-	-
X	Profit/(Loss) Before Tax (VIII-IX)	364.84	167.72	156.10	323.82
XI	Tax expense				
	(1) Current tax	92.93	44.68	41.02	85.70
	(2) Deferred tax	(0.56)	(1.06)	(0.12)	(1.18)
	(3) Short/(Excess) provision of earlier year	-	4.38	-	4.38
XII	Total Tax Expense	92.37	48.00	40.90	88.90
XIII	Profit/(Loss) for the period from continuing operations (X-XII)	272.47	119.72	115.20	234.92
	Profit/(Loss) from discontinuing operations before tax	-	-	-	-
	Tax expense of discontinuing operations	-	-	-	-
XIII	Profit/(Loss) from discontinuing operations after tax	-	-	-	-
XIV	Profit/(Loss) for period before minority interest	272.47	119.72	115.20	234.92
	Share of profit/(loss) of associates	-	-	-	-
	Profit/Loss of minority interest	-	-	-	-
XV	Other comprehensive income / (expense)				
(A)	Items that will not be reclassified to profit or loss				
a)	Remeasurement gain/(loss) on defined benefit plans	(2.22)	(1.49)	(1.32)	(2.81)
b)	Income tax effect on above	0.56	0.38	0.33	0.71
B)	Items that will be reclassified to profit or loss				
	Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income / (Loss)	(1.66)	(1.11)	(0.99)	(2.10)
XVI	Total Comprehensive Income (XIV+XV)	270.81	118.61	114.21	232.82
XVII	Net Profit/(Loss) for the period	270.81	118.61	114.21	232.82
XVIII	Details of Equity Share Capital				
	Paid-up Equity Share Capital	1,550.00	1,540.00	1,540.00	1,540.00
	Face Value of equity share capital	Rs 10/-	Rs 10/-	Rs 10/-	Rs 10/-
	Other Equity	-	-	-	-
XIX	Earnings per equity share:				
(a)	Basic EPS from continuing and discontinued operations (not annualised)	1.77	0.79	0.74	1.53
(b)	Diluted EPS from continuing and discontinued operations (not annualised)	1.77	0.79	0.74	1.53

NOTES:

- This is the first period for which the Company has prepared financial results in compliance with Ind AS. Prior to April 1, 2025, the Company had prepared its Financial Statement in accordance with the Accounting Standards notified under 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 (Previous GAAP)
- The Company has adopted Ind AS (Indian Accounting Standards) w.e.f April 1, 2025. The Reconciliation of Net Profit reported in accordance with Previous GAAP to total comprehensive Income in accordance with Ind AS for the year ended 30th September, 2024 as mentioned in point number 1 is given below.

Particulars	Rs. In Lakhs	
	Half-Year Ended on 30th September 2024 (Unaudited)	
	Consolidated	Standalone
Net Profit for the period under previous Indian GAAP	517.38	112.75
Adjustments on account of:		
Employee benefit expense	1.32	1.32
Interest Income	0.18	0.18
Interest expense on security deposit	(0.16)	(0.16)
Interest expense on lease	(5.54)	-
Rent expense	29.43	-
Depreciation	(25.02)	-
Tax	(8.39)	1.11
Conversion of JV to Subsidiary on account of IND AS	395.84	-
FCTR	(3.21)	-
Net Profit for the period as per IND AS	901.83	115.20

- 3 The standalone/Consolidated financial results of the company have been prepared in, accordance with Indian Accounting standards (Ind AS) as prescribed under section 133 of the companies Act 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (LODR) Regulation, 2015. The company has also reclassified the previous figures in accordance with the requirements applicable in the current period.
- 4 The Statutory Auditors have conducted Limited Review of the above mentioned half yearly financial results of September 30, 2025, as required by regulation 33 of SEBI (LODR) regulations, 2015.
- 5 Basic earnings per share are calculated by dividing the profit after Tax for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of 6 lakhs number of equity share warrants
- 6 The company has approved the allotment of 7 Lakhs convertible warrants at Rs. 151 per warrant in its extra ordinary general meeting held on April 9, 2025 and the subsequent in principle approval is granted by the NSE. The company has already converted 1 lakhs warrants into equity shares during the half year period ending on 30th September 2025. The balance 6 lakhs warrants are outstanding and the company has received the 25% of the issue price for such warrants. The warrants are convertible into equal number of equity share and the conversion option can be exercised at any time during the period of 18 months from the date of allotment of the said warrants.
- 7 The Statutory Auditors of the Company have carried out Limited Review of the financial results for the Year ended on September 30, 2025 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The above financial results have been audited and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 14th November, 2025.
- 8 The aforesaid results have been filed with Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are also available on the Stock Exchanges websites and on the website of the Company.
- 9 The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018.
- 10 There are no investors complaints pending as on 30 september, 2025.
- 11 The figures for half year ended 31st March, 2025 are the balancing figures between the unaudited IND AS numbers in respect of Financial Year 2024-25 and the published unaudited figures of the Half Year ended September 30, 2024, which were subject to limited review.
- 12 The name of the company has been changed from Unihealth Consultancy Limited to Unihealth Hospitals Limited vide MCA certificate of Incorporation dated 14th October, 2024.
- 13 Segment information is presented in the "Consolidated Financial Results" as permitted under the Ind AS 108 -'Operating Segments'.
- 14 The proceeds from the Equity shares IPO issued during FY 23-24 was amounting to Rs 5654.88 lakhs. The object and proposed utilization of IPO Proceeds and amount utilized as on September 30th , 2025 is as under:-

Object	Amount Utilized
Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL.	1700.00
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure	281.44
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion*	237.50
Investment in our subsidiaries UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa*	1350.00
General Corporate Purpose	1093.08
Issue Expenses	814.30

* The original object as disclosed in the offer document was further altered by passing a resolution to vary the utilisation of proceeds raised by the Company through an initial public offering of equity shares (the 'IPO') made in pursuance of the Prospectus dated September 14, 2023 (the 'Prospectus') and reallocate the unutilized proceeds for the objects as set out in the Postal Ballot Notice, have been passed with requisite majority on Wednesday, June 26, 2024. Out of initial proposed amount i.e. Rs. 1587.50 Lakhs, Rs.1350 Lakhs were reallocated for investing as equity and debt in UMC Hospitals Private Limited, a subsidiary of the Company in India and in Unihealth Holdings Limited, the wholly owned subsidiary of the Company in Mauritius, to support expansion and acquisition of projects across India and Africa, in furtherance of the current objects of the Company.

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)



Akshay M Parmar
Managing Director

DIN:01533004

Place : Mumbai

Date: 14th November, 2025




UNIHEALTH HOSPITAL LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2025

Particulars	(Rs. In lakhs)		
	As at 30th September, 2025	As at 31st March 2025	As at 1st April, 2024
	Unaudited Refer Note 1	Unaudited Refer Note 1	Unaudited Refer Note 1
A. ASSETS			
(1) Non Current Assets			
(a) Property plant and equipment & Intangible Assets	300.92	314.63	308.76
Capital work in progress	-	-	-
Goodwill	-	-	-
(b) Right-of-use assets	-	-	-
(c) Financial assets			
Investments	3,049.73	3,049.73	1,837.36
Other	3,165.11	2,598.17	1,572.64
(d) Investment Property	-	-	-
(e) Deferred tax asset	-	-	-
Total Non-Current Assets	6,515.76	5,962.53	3,718.76
(2) Current Assets			
(a) Inventories	-	-	-
(b) Financial assets	-	-	-
(i) Investments	-	-	-
(ii) Trade receivables	498.22	290.72	260.78
(iii) Cash and cash equivalents	213.23	16.34	964.28
(iv) Bank Balance other than (iii) above	-	400.00	1,700.00
(v) Loans and advances	-	-	-
(vi) Other financial assets	194.44	172.59	4.01
(c) Current Tax assets	217.04	189.99	194.45
(d) Other current assets	4.72	6.34	4.20
Total Current Assets	1,127.65	1,075.98	3,127.72
Total Assets	7,643.41	7,038.51	6,846.48
B. EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital	1,550.00	1,540.00	1,540.00
(b) Other equity	5,768.45	5,130.69	4,899.99
Total Equity	7,318.45	6,670.69	6,439.99
(2) Non-current Liabilities			
(a) Financial Liabilities			
(i) borrowings	78.00	78.00	329.97
(ii) Lease Liabilities	-	-	-
(b) Provisions	28.95	26.16	25.85
(c) Deferred tax liabilities	5.57	6.13	6.60
Total Non-Current Liabilities	112.52	110.29	362.42
(3) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	-	-	-
(ii) Lease Liabilities	-	-	-
(iii) Trade Payables	-	-	-
(a) Total outstanding dues of micro enterprises	40.84	11.19	0.28
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.07	1.77	2.55
(iv) Other current financial Liabilities	39.96	214.10	22.53
(b) Provisions	102.98	25.83	15.58
(c) Other current Liabilities	28.59	4.69	3.83
Total Current Liabilities	212.44	257.53	44.77
Total	7,643.41	7,038.51	6,846.48

For and on behalf of Board of
Unihealth Hospitals Limited
(Formerly known as Unihealth Consultancy Limited)


Akshay M Parmar
Managing Director
DIN: 01533004
Place : Mumbai
Date: 14th November, 2025



UNIHEALTH HOSPITAL LIMITED
(Formerly known as UNIHEALTH CONSULTANCY LIMITED)
H-13/14 Everest, 156, Tardeo Road, Mumbai, Maharashtra 400034
CIN : L85100MH2010PLC200491

UNAUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30TH SEP

Particulars	Half Year Period ended, 30th September 2025	For the year ended, 31st March 2025
	Unaudited	Unaudited
	Refer Note 1	Refer Note 1
A Cash flow from operating activities		
Net profit before tax	364.84	323.82
Adjustments for:		
Depreciation/amortization	12.43	28.23
Short/Excess Provision for Tax	-	-
Finance Cost	8.27	3.25
Foreign exchange (gain)/Loss	(103.70)	(45.19)
Miscellaneous Income	-	-
Loss On Sale Of Fixed Assets	1.62	-
Interest on FD	(5.31)	(82.87)
Interest on Loan given	(152.48)	(196.31)
Operating profit before working capital changes	125.67	30.93
Changes in assets and liabilities:		
Increase / (decrease) in trade payables	28.01	10.08
Increase / (decrease) in other financial liabilities	73.90	0.86
Increase / (decrease) in provisions	77.72	3.38
Increase / (decrease) in other current financial liabilities	(75.90)	227.44
(Increase) / decrease in other financial assets and other curr	(587.18)	(1,196.25)
(Increase) / decrease in short term loan and advances	-	-
(Increase) / Decrease in trade receivables	(207.50)	(29.94)
(Increase)/Decrease in Current Tax assets	(27.05)	4.47
Cash (used in)/ generated from operating activities	(642.33)	(949.04)
Income tax paid	(92.93)	(85.70)
Net cash from/ (used in) from operating activities (A)	(735.26)	(1,034.74)
B Cash flow from Investing activities		
Proceeds/(investments) in fixed deposits & shares (net)	-	(1,212.37)
Purchase of property, plant and equipment	(0.33)	(34.10)
Interest received	5.31	82.87
Interest on loan given	152.48	196.31
maturity proceeds of fixed deposits	400.00	1,300.00
Net cash from/ (used in) from investing activities (B)	557.46	332.71
C Cash flow from Financing activities		
Proceeds from Issuance of Share Capital	151.00	-
Proceeds from issue of Share warrants	226.50	-
Share Issue Expenses	-	-
Proceeds/ (Repayment) of Borrowings	-	(251.97)
Foreign exchange (gain)/Loss	5.46	9.31
Miscellaneous Income	-	-
Foreign exchange (gain)/Loss	-	-
Interest on FD	-	-
Interest on Loan given	-	-
Finance cost	(8.27)	(3.25)
Net cash from / (used in) from financing activities (C)	374.69	(245.91)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	196.89	(947.94)
Cash and cash equivalents at the beginning of the year	16.34	964.28
Cash and cash equivalents at the end of the year	213.23	16.34


Notes:

- The cash flow statement has been prepared in accordance with the requirements of Indian Accounting standard - 7 - Cash flow Statement issued in terms of section 133 of the Companies Act, 2013.

For and on behalf of Board of

Unihealth Hospitals Limited

(Formerly known as Unihealth Consultancy Limited)



Akshay M Parmar
Managing Director

DIN:01533004

Place : Mumbai

Date: 14th November, 2025

